NCX 4040, a nitric oxide-donating aspirin, exerts anti-inflammatory effects through inhibition of IκB-α degradation in human monocytes

Journal of Immunology

Volumn 184, Issue 4, 2010, Pages 2140-2147

  Ricciotti, Emanuela ^a,d   Dovizio, Melania ^a   Di Francesco, Luigia ^a   Anzellotti, Paola ^a   Salvatore, Tania ^a   Di Francesco, Andrea ^a   Sciulli, Maria G ^a   Pistritto, Giuseppa ^b   Monopoli, Angela ^c   Patrignani, Paola ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c NicOx Research Institute   (Italy)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ACETYLSALICYLIC ACID DERIVATIVE; ANTIINFLAMMATORY AGENT; CYCLIC GMP; CYCLOOXYGENASE 2; I KAPPA B; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; NCX 4040; NITRIC OXIDE; PROSTAGLANDIN E2; PROTEASOME; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYCLOOXYGENASE 1; DRUG DERIVATIVE; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; NITRIC OXIDE DONOR; NITRO DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PTGS1 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD; CELL ISOLATION; CELL LYSATE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME STABILITY; HUMAN; HUMAN CELL; ISOMERISM; MONOCYTE; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SUPERNATANT; UBIQUITINATION; ADULT; BIOSYNTHESIS; CHEMISTRY; DRUG ANTAGONISM; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; THROMBOCYTE; TUMOR CELL LINE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOOD PLATELETS; CELL LINE, TUMOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; HUMANS; I-KAPPA B PROTEINS; LIPOPOLYSACCHARIDES; MONOCYTES; NITRIC OXIDE DONORS; NITRO COMPOUNDS; SIGNAL TRANSDUCTION;

EID: 77949911051     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903107     Document Type: Article

References (50)

1. Vane, J. R. 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231: 232-235.
2. Lecomte, M., O. Laneuville, C. Ji, D. L. DeWitt, and W. L. Smith. 1994. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J. Biol. Chem. 269: 13207-13215.
3. 2 synthase. Nat. Struct. Biol. 2: 637-643.
4. Vane, J. R., Y. S. Bakhle, and R. M. Botting. 1998. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38: 97-120.
5. Smith, W. L., D. L. DeWitt, and R. M. Garavito. 2000. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69: 145-182.
6. Kang, Y. J., U. R. Mbonye, C. J. DeLong, M. Wada, and W. L. Smith. 2007. Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Prog. Lipid Res. 46: 108-125.
7. Kargman, S., S. Charleson, M. Cartwright, J. Frank, D. Riendeau, J. Mancini, J. Evans, and G. O'Neill. 1996. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 111: 445-454.
8. Patrono, C., P. Patrignani, and L. A. García Rodríguez. 2001. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J. Clin. Invest. 108: 7-13.
9. Vane, J. R., and R. M. Botting. 2001. Formation and actions of prostaglandins and inhibition of their synthesis. In Therapeutic roles of selective COX-2 inhibitors. J. R. Vane, and R. M. Botting, eds. Wiliam Harvey Press, London, p. 1-47.
10. Crofford, L. J. 1997. COX-1 and COX-2 tissue expression: implications and predictions. J. Rheumatol. Suppl. 49: 15-19.
11. Cao, Y., and S. M. Prescott. 2002. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J. Cell. Physiol. 190: 279-286.
12. del Soldato, P., R. Sorrentino, and A. Pinto. 1999. NO-aspirins: a class of new antiinflammatory and antithrombotic agents. Trends Pharmacol. Sci. 20: 319-323.
13. Bandarage, U. K., and D. R. Janero. 2001. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs: novel gastrointestinal-sparing drugs. Mini Rev. Med. Chem. 1: 57-70.
14. Velázquez, C., P. N. Praveen Rao, and E. E. Knaus. 2005. Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies. J. Med. Chem. 48: 4061-4067.
15. Kashfi, K., S. Borgo, J. L. Williams, J. Chen, J. Gao, A. Glekas, F. Benedini, P. Del Soldato, and B. Rigas. 2005. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. J. Pharmacol. Exp. Ther. 312: 978-988.
16. Grosser, N., and H. Schröder. 2000. A common pathway for nitric oxide release from NO-aspirin and glyceryl trinitrate. Biochem. Biophys. Res. Commun. 274: 255-258.
17. Carini, M., G. Aldini, M. Orioli, and R. Maffei Facino. 2002. In vitro metabolism of a nitroderivative of acetylsalicylic acid (NCX4016) by rat liver: LC and LC-MS studies. J. Pharm. Biomed. Anal. 29: 1061-1071.
18. Gao, J., K. Kashfi, and B. Rigas. 2005. In vitro metabolism of nitric oxide-donating aspirin: the effect of positional isomerism. J. Pharmacol. Exp. Ther. 312: 989-997.
19. Tesei, A., W. Zoli, F. Fabbri, C. Leonetti, M. Rosetti, M. Bolla, D. Amadori, and R. Silvestrini. 2008. NCX 4040, an NO-donating acetylsalicylic acid derivative: efficacy and mechanisms of action in cancer cells. Nitric Oxide 19: 225-236.
20. Dunlap, T., S. O. Abdul-Hay, R. E. Chandrasena, G. K. Hagos, V. Sinha, Z. Wang, H. Wang, and G. R. Thatcher. 2008. Nitrates and NO-NSAIDs in cancer chemoprevention and therapy: in vitro evidence querying the NO donor functionality. Nitric Oxide 19: 115-124.
21. Hulsman, N., J. P. Medema, C. Bos, A. Jongejan, R. Leurs, M. J. Smit, I. J. de Esch, D. Richel, and M. Wijtmans. 2007. Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. J. Med. Chem. 50: 2424-2431.
22. Kashfi, K., and B. Rigas. 2007. The mechanism of action of nitric oxide-donating aspirin. Biochem. Biophys. Res. Commun. 358: 1096-1101.
23. Zhang, G., and S. Ghosh. 2000. Molecular mechanisms of NF-κB activation induced by bacterial lipopolysaccharide through Toll-like receptors. J. Endotoxin Res. 6: 453-457.
24. Karin, M., and Y. Ben-Neriah. 2000. Phosphorylation meets ubiquitination: the control of NF-kB activity. Annu. Rev. Immunol. 18: 621-663.
25. Patrignani, P., M. R. Panara, A. Greco, O. Fusco, C. Natoli, S. Iacobelli, F. Cipollone, A. Ganci, C. Créminon, J. Maclouf, and C. Patrono. 1994. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J. Pharmacol. Exp. Ther. 271: 1705-1712.
26. 2 production in healthy subjects. Thromb. Res. 17: 317-327.
27. Garcia-Calvo, M., E. P. Peterson, B. Leiting, R. Ruel, D. W. Nicholson, and N. A. Thornberry. 1998. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J. Biol. Chem. 273: 32608-32613.
28. Lee, D. H., and A. L. Goldberg. 1998. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 8: 397-403.
29. Garthwaite, J., E. Southam, C. L. Boulton, E. B. Nielsen, K. Schmidt, and B. Mayer. 1995. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol. Pharmacol. 48: 184-188.
30. Thornberry, N. A., H. G. Bull, J. R. Calaycay, K. T. Chapman, A. D. Howard, M. J. Kostura, D. K. Miller, S. M. Molineaux, J. R. Weidner, J. Aunins, et al. 1992. A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature 356: 768-774.
31. Dinarello, C. A., D. Novick, A. J. Puren, G. Fantuzzi, L. Shapiro, H. Mühl, D. Y. Yoon, L. L. Reznikov, S. H. Kim, and M. Rubinstein. 1998. Overview of interleukin-18: more than an interferon-γ inducing factor. J. Leukoc. Biol. 63: 658-664.
32. Fiorucci, S., L. Santucci, G. Cirino, A. Mencarelli, L. Familiari, P. D. Soldato, and A. Morelli. 2000. IL-1b converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs. J. Immunol. 165: 5245-5254.
33. Qureshi, N., S. N. Vogel, C. Van Way, III, C. J. Papasian, A. A. Qureshi, and D. C. Morrison. 2005. The proteasome: a central regulator of inflammation and macrophage function. Immunol. Res. 31: 243-260.
34. Kisselev, A. F., and A. L. Goldberg. 2001. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 8: 739-758.
35. Goldberg, A. L., and K. Rock. 2002. Not just research tools - proteasome inhibitors offer therapeutic promise. Nat. Med. 8: 338-340.
36. Rigas, B., and K. Kashfi. 2004. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol. Med. 10: 324-330.
37. Cipollone, F., P. Patrignani, A. Greco, M. R. Panara, R. Padovano, F. Cuccurullo, C. Patrono, A. G. Rebuzzi, G. Liuzzo, G. Quaranta, and A. Maseri. 1997. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 96: 1109-1116. (Pubitemid 27344211)
38. Patrignani, P. 2003. Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb. Res. 110: 281-286.
39. Patrono, C., B. Coller, J. E. Dalen, G. A. FitzGerald, V. Fuster, M. Gent, J. Hirsh, and G. Roth. 2001. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 119: 39S-63S.
40. Tegeder, I., J. Pfeilschifter, and G. Geisslinger. 2001. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 15: 2057-2072.
41. Kopp, E., and S. Ghosh. 1994. Inhibition of NF-κB by sodium salicylate and aspirin. Science 265: 956-959. (Pubitemid 2115182)
42. Yin, M. J., Y. Yamamoto, and R. B. Gaynor. 1998. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 396: 77-80.
43. Blechman, W. J., F. R. Schmid, P. A. April, C. H. Wilson, Jr., and C. D. Brooks. 1975. Ibuprofen or aspirin in rheumatoid arthritis therapy. JAMA 233: 336-340.
44. Dikshit, P., M. Chatterjee, A. Goswami, A. Mishra, and N. R. Jana. 2006. Aspirin induces apoptosis through the inhibition of proteasome function. J. Biol. Chem. 281: 29228-29235.
45. Roderick, P. J., H. C. Wilkes, and T. W. Meade. 1993. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br. J. Clin. Pharmacol. 35: 219-226.
46. Wallace, J. L., and P. Del Soldato. 2003. The therapeutic potential of NONSAIDs. Fundam. Clin. Pharmacol. 17: 11-20.
47. Chen, C. G., J. Malliaros, M. Katerelos, A. J. d'Apice, and M. J. Pearse. 1996. Inhibition of NF-κB activation by a dominant-negative mutant of IkBα. Mol. Immunol. 33: 57-61.
48. Elsasser, S., and D. Finley. 2005. Delivery of ubiquitinated substrates to protein-unfolding machines. Nat. Cell Biol. 7: 742-749.
49. Goswami, A., P. Dikshit, A. Mishra, S. Mulherkar, N. Nukina, and N. R. Jana. 2006. Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction. Biochem. Biophys. Res. Commun. 342: 184-190.
50. Connelly, L., M. Palacios-Callender, C. Ameixa, S. Moncada, and A. J. Hobbs. 2001. Biphasic regulation of NF-κB activity underlies the pro- and antiinflammatory actions of nitric oxide. J. Immunol. 166: 3873-3881. (Pubitemid 32224913)